Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Novartis ag crawled time : 12:00 save search
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
NAMS | $19.98 2.78% 2.7% 140K
|
n/a
|
| O: 6.23%
H: 2.77%
C: -10.21%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.47%
H: 0.23%
C: -0.99%
pharma business
AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.08%
H: 0.15%
C: -0.44%
AUTL | $4.51 -6.04% -6.43% 1.4M
|
Health Technology
|
| O: 2.53%
H: 1.85%
C: -2.31%
medical
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
Published: 2024-03-22 (Crawled : 12:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.17%
H: 0.28%
C: -0.01%
fabhalta first chmp positive novartis
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
Published: 2024-03-07 (Crawled : 12:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.04%
H: 0.44%
C: -1.51%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -2.08%
H: 0.13%
C: -0.57%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.36%
H: 0.34%
C: -0.54%
XFOR | $1.255 4.58% 4.38% 3M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: -4.98%
EYPT | $17.665 0.94% 0.93% 1.5M
|
Health Technology
|
| O: 2.56%
H: 1.37%
C: -4.13%
AQST | $4.11 -8.67% -9.49% 2.3M
|
Health Technology
|
| O: 1.79%
H: 12.3%
C: 10.94%
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 1.11%
H: 0.96%
C: 0.65%
Clinical trials market size in US to grow by USD 5.9 billion from 2022 to 2027, The rise in the number of clinical trials of drugs is the key factor driving market growth, Technavio
Published: 2024-03-06 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.0%
H: 0.8%
C: 0.8%
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: 0.64%
H: 1.7%
C: 0.54%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.2%
H: 0.71%
C: 0.33%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
ICLR | $288.32 -1.2% -1.21% 640K
|
Health Technology
|
| O: 2.54%
H: 0.22%
C: -2.44%
trials key market
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
Published: 2024-01-02 (Crawled : 12:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.86%
H: 1.81%
C: 0.9%
VYGR | $7.5 -0.66% -0.67% 520K
|
Health Technology
|
| O: 24.76%
H: 11.3%
C: -14.53%
SGMO | $0.5143 6.02% 5.68% 1M
|
Health Technology
|
| O: -0.17%
H: 9.33%
C: 2.56%
NBIX M | $132.03 -0.39% -0.39% 560K
|
Health Technology
|
| O: -1.18%
H: 2.4%
C: 1.18%
license collaboration novartis therapeutics agreement
Bioluminescence Ventures Emerges from Stealth with $477M AUM
Published: 2023-11-01 (Crawled : 12:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 2.52%
H: 0.04%
C: 0.04%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.16%
H: 0.7%
C: 0.57%
Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors
Published: 2023-08-29 (Crawled : 12:00) - globenewswire.com
ERAS | $1.79 0.0% 570K
|
|
| O: 0.0%
H: 1.52%
C: -2.09%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.18%
H: 1.41%
C: 1.1%
tumors trial plus
Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years
Published: 2023-08-28 (Crawled : 12:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.06%
H: 0.06%
C: -0.51%
leqvio six beyond novartis
Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company
Published: 2023-08-23 (Crawled : 12:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.56%
H: 0.1%
C: -0.32%
growth
Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs
Published: 2023-07-20 (Crawled : 12:00) - globenewswire.com
ACRV P | $9.405 -10.77% -12.07% 630K
|
|
| O: -3.91%
H: 4.07%
C: 3.12%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 2.78%
H: 0.0%
C: -1.86%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.51%
H: 0.72%
C: 0.33%
biotech therapeutics
US FDA approves expanded indication for Novartis Leqvio® (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease
Published: 2023-07-10 (Crawled : 12:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.44%
H: 0.73%
C: 0.48%
leqvio fda disease treatment risk novartis heart
Precision Medicine Market size to grow by USD 54.07 billion from 2022 to 2027|Growing prevalence of chronic diseases to boost market growth - Technavio
Published: 2023-07-04 (Crawled : 12:00) - prnewswire.com
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
| Email alert
Add to watchlist
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
| Email alert
Add to watchlist
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
| Email alert
Add to watchlist
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
| Email alert
Add to watchlist
growth market
Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy
Published: 2023-06-30 (Crawled : 12:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: -4.47%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.74%
H: 0.81%
C: 0.81%
novartis agreement
Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors
Published: 2023-06-08 (Crawled : 12:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.32%
H: 0.0%
C: -0.62%
CADL | $5.17 -5.31% -5.61% 520K
|
|
| O: 1.99%
H: 5.19%
C: 3.25%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.26%
H: 1.08%
C: 0.91%
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: 0.59%
H: 0.0%
C: -2.74%
therapeutics
Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
Published: 2023-06-02 (Crawled : 12:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.6%
H: 1.07%
C: 0.29%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.03%
H: 0.84%
C: 0.82%
kisqali breast risk novartis
Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update
Published: 2023-05-09 (Crawled : 12:00) - precisionbiosciences.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -2.35%
H: 1.06%
C: 0.48%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.38%
H: 0.39%
C: 0.18%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.22%
H: 0.89%
C: -0.79%
DTIL | $9.75 -9.05% -9.95% 170K
|
Health Technology
|
| O: -2.94%
H: 5.45%
C: 3.03%
business update financial results
Novartis Entresto receives positive CHMP opinion for pediatric heart failure
Published: 2023-03-31 (Crawled : 12:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.95%
H: 2.14%
C: 2.14%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.22%
H: 0.45%
C: 0.24%
chmp positive novartis heart
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
Published: 2023-03-09 (Crawled : 12:00) - precisionbiosciences.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -5.6%
H: 1.19%
C: 1.19%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -3.04%
H: 0.16%
C: -0.9%
DTIL | $9.75 -9.05% -9.95% 170K
|
Health Technology
|
| O: 0.87%
H: 2.59%
C: -12.07%
year financial update results
Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets
Published: 2023-03-06 (Crawled : 12:00) - ir.voyagertherapeutics.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 2.04%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.34%
H: 0.76%
C: -0.06%
VYGR | $7.5 -0.66% -0.67% 520K
|
Health Technology
|
| O: 5.47%
H: 5.45%
C: 3.24%
disease license therapeutics payment
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.